Julia Glade Bender

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren et al. · The Lancet Oncology · 2019 · 343 citations

Medicine, Oncology, Pharmacotherapy +17

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn et al. · The Lancet Oncology · 2017 · 273 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

Julia Glade Bender, Peter C. Adamson, Joel M. Reid et al. · Journal of Clinical Oncology · 2008 · 251 citations

Pharmacy, Oncology, Pharmacology +16

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Benjamin A. Nacev, Francisco Sánchez-Vega, Shaleigh Smith et al. · Nature Communications · 2022 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors

Marian H. Harris, Steven G. DuBois, Julia Glade Bender et al. · JAMA Oncology · 2016 · 204 citations · Full text

Medicine, Oncology, Pediatrics +17